News Aussie pharma CSL in talks to buy Swiss firm...

Aussie pharma CSL in talks to buy Swiss firm Vifor Pharma for USD 7B

-

CSL, the Australian giant, is in talks to buy Vifor Pharma in a deal that is valued at $7B, or A$10B. Vifor Pharma is a Swiss pharma company.
Analysts predict that as CSL buys Vifor Pharma it will be able to expand on its current portfolio to include manufacturing of drugs for kidney and heart disease. Currently, CSL pharmaceutical company is the largest manufacturer of blood plasma treatments.
The deal has been in the works since early 2021, but as the talks have become serious, Vifor Pharma’s shares have risen by almost a fifth, closing in at a 21% increase in the Swiss index.
CSL pharmaceutical company had seen a dip in collections for plasma due to COVID-19 pandemic restrictions. This is due to the fact that it is dependent on people coming for blood to be purchased by the company.
As CSL buys Vifor pharma, they will gain the ability to expand on their kidney transplant franchise, which is currently in its infancy stage. However, this will be a step away from their focus on the therapeutic area of medicine. Both companies have stated that they will not be commenting on the deal.

Latest news

Patient-Centric Clinical Trials And The Role Of A Travel Concierge

Many people find booking plane tickets, arranging road transportation and overnight lodging overwhelming. Add into that mix...

China forces insulin price cuts resulting in pullback for global pharma players

Xinhua, a Chinese news channel, commented on the price cut on insulin which was brought on by...

Aussie pharma CSL in talks to buy Swiss firm Vifor Pharma for USD 7B

CSL, the Australian giant, is in talks to buy Vifor Pharma in a deal that is valued...
- Advertisement -

Must read

Surrounded by controversy, FDA approves Biogen’s Alzheimer’s drug Aduhelm

In the middle of the debate about the Alzheimer’s drug approval, the United States FDA has authorized Aduhelm

Amgen’s KRAS drug gets early FDA approval for lung cancer with specific mutation

On Friday, the United States FDA (Food and Drug Administration) has authorized a medication of Amgen Biopharmaceutical in patients with NSCLC

You might also likeRELATED
Recommended to you

Nominations for Top Industry Leaders Awards are now open!